past
halfcenturi
medic
advanc
led
increas
world
popul
immunosuppress
individu
includ
receiv
immunosuppress
therapi
acquir
immunosuppress
diseas
million
worldwid
human
immunodefici
viru
hiv
aid
individu
live
longer
known
primari
immunodefici
sever
immunocompromis
diagnos
hematolog
malign
solid
organ
tumor
receiv
immunosuppress
therapi
chemotherapi
andor
solid
organ
stem
cell
transplant
individu
annual
receiv
solid
organ
transplant
sot
worldwid
hematolog
malign
diseas
treat
hematopoiet
stem
cell
transplant
hsct
annual
leav
individu
immunosuppress
long
period
even
larger
number
individu
receiv
immunosuppress
chemotherapi
make
immunocompromis
individu
larger
part
popul
influenza
pandem
twentieth
centuri
epidemiolog
studi
shown
sever
immunosuppress
major
comorbid
place
individu
highest
risk
sever
morbid
mortal
due
influenza
infect
patient
aid
increas
durat
diseas
due
influenza
higher
incid
pneumonia
lead
increas
mortal
studi
hospit
patient
leukemia
influenza
report
pneumonia
mortal
recent
pandem
studi
report
similarli
high
level
lower
respiratori
tract
diseas
need
hospit
hematolog
malign
solid
tumor
undergo
chemotherapi
similarli
larg
retrospect
studi
hsct
recipi
patient
develop
influenza
infect
develop
pneumonia
recent
studi
hsct
patient
demonstr
develop
pneumonia
influenza
infect
mortal
high
sot
nosocomi
outbreak
sever
complic
influenza
myocard
sever
pneumon
report
even
previous
vaccin
multicent
studi
infect
sot
recipi
report
individu
infect
develop
pneumonia
requir
intens
care
mortal
high
influenza
follow
sot
lead
higher
morbid
mortal
rate
increas
rate
influenza
pneumonia
follow
lung
transplant
mortal
rate
observ
sot
recipi
infect
influenza
addit
increas
morbid
mortal
follow
infect
sever
immunocompromis
patient
report
show
prolong
influenza
shed
associ
intrahost
viral
evolut
includ
antigen
drift
within
singl
immunosuppress
host
develop
antivir
resist
therapi
simultan
coinfect
influenza
subtyp
rigor
vaccin
program
improv
pharmacotherapi
decreas
impact
influenza
gener
popul
howev
influenza
still
remain
seriou
threat
sever
immunocompromis
individu
pandem
remind
still
unclear
well
current
vaccin
strategi
current
pharmacotherapi
perform
prevent
mitig
ill
immunocompromis
individu
primari
goal
studi
compar
natur
histori
influenza
infect
sever
immunocompromis
individu
immunocompromis
care
examin
symptom
sign
infect
virolog
measur
immunolog
studi
clinic
paramet
perform
investig
natur
pathogenesi
influenza
group
sever
immunocompromis
host
subject
recruit
nation
institut
health
nih
clinic
center
bethesda
md
washington
hospit
center
washington
dc
irb
approv
protocol
influenza
nonimmunocompromis
immunocompromis
host
clinicaltrialsgov
identifi
particip
legal
guardian
sign
inform
consent
medic
attend
patient
diagnosi
influenza
recruit
histori
physic
perform
initi
diagnost
specimen
collect
nasal
wash
blood
sampl
collect
everi
day
first
day
postdiagnosi
nasal
wash
perform
use
method
describ
neclerio
followup
examin
sampl
collect
week
week
perform
subject
shed
viru
extend
period
time
follow
throughout
cours
infect
sampl
perform
infect
resolv
clinic
data
compil
statist
analys
perform
use
graphpad
prism
softwar
initi
diagnosi
made
clinic
laboratori
facil
sampl
collect
sampl
test
use
matrix
onestep
taqman
realtim
revers
transcript
polymeras
chain
reaction
rtpcr
assay
describ
elsewher
andor
luminex
multiplex
respiratori
viral
panel
kit
luminex
corp
austin
tx
viral
isol
use
standard
mdck
cultur
method
type
subtyp
determin
rtpcr
sequenc
hemagglutinin
ha
neuraminidas
na
gene
comparison
known
influenza
sequenc
genbank
total
nucleic
acid
extract
sampl
use
nuclisen
easymag
system
viral
complementari
dna
cdna
revers
transcrib
use
influenza
specif
primer
pcr
perform
use
custom
primer
amplifi
viral
gene
segment
tabl
sanger
sequenc
perform
pcr
product
serum
nasal
wash
cytokin
measur
use
bioplex
pro
human
cytokin
assay
biorad
bioplex
biorad
hercul
ca
follow
cytokin
measur
interleukin
interleukin
interleukin
interleukin
interleukin
interleukin
interleukin
interleukin
interleukin
interleukin
interleukin
interleukin
granulocyt
colonystimul
factor
gcsf
granulocyt
macrophag
colonystimul
factor
gmcsf
interferon
monocyt
chemoattract
protein
macrophag
inflammatori
protein
tumor
necrosi
factor
control
use
collect
healthi
volunt
result
compil
statist
analysi
perform
use
graphpad
prism
softwar
eightysix
influenza
patient
enrol
period
classifi
sever
immunocompromis
primarili
due
malign
condit
treat
either
recent
hsct
immunosuppress
therapi
remain
patient
classifi
nonimmunocompromis
includ
individu
without
underli
comorbid
demograph
individu
summar
tabl
note
individu
studi
vaccin
within
year
becom
infect
influenza
major
nonimmunocompromis
individu
overweight
obes
although
patient
studi
nonsmok
nonimmunocompromis
particip
current
smoker
wherea
current
smoker
immunocompromis
group
hematolog
condit
common
underli
diagnosi
patient
undergon
hsct
within
year
influenza
infect
immunocompromis
group
form
graftvshost
diseas
gvhd
tabl
undergo
hsct
undergo
immunosuppress
therapi
tabl
nonimmunocompromis
group
patient
chronic
comorbid
includ
hypertens
diabet
mellitu
coronari
arteri
diseas
asthma
chronic
obstruct
pulmonari
diseas
wellcontrol
hiv
infect
full
symptom
evalu
time
diagnosi
perform
patient
tabl
common
symptom
note
dri
cough
fever
headach
chill
coryza
product
cough
sweat
also
common
rang
symptom
observ
includ
short
breath
chest
pain
interest
preval
multipl
gastrointestin
neurolog
symptom
major
symptom
preval
nonimmunocompromis
group
includ
statist
higher
dri
cough
chill
sweat
myalgia
short
breath
chemosi
neurolog
symptom
gastrointestin
symptom
slightli
common
immunocompromis
group
decreas
appetit
observ
symptom
statist
preval
tabl
fiftyseven
patient
complet
physic
exam
document
diagnosi
overal
trend
physic
exam
abnorm
observ
nonimmunocompromis
group
pulmonari
abnorm
particular
statist
preval
tabl
pulmonari
abnorm
exam
common
find
overal
cardiac
abnorm
note
patient
mostli
consist
tachycardia
abnorm
minim
mani
individu
signific
find
immunocompromis
patient
requir
hospit
upon
diagnosi
six
patient
immmunocompromis
group
requir
intens
care
mechan
ventil
contrast
patient
p
nonimmunocompromis
group
requir
hospit
none
requir
intens
care
treatment
p
death
observ
immunocompromis
group
immunocompromis
patient
also
exhibit
significantli
longer
length
ill
p
mean
shed
day
wherea
nonimmunocompromis
patient
observ
shed
mean
day
figur
consist
differ
radiolog
examin
observ
chest
comput
tomographi
ct
chest
radiograph
cxr
perform
time
diagnosi
patient
recruit
major
immunocompromis
patient
radiolog
studi
perform
wherea
less
perform
nonimmunocompromis
patient
radiolog
examin
show
new
abnorm
time
diagnosi
immunocompromis
patient
significantli
like
new
imag
abnorm
compar
nonimmunocompromis
group
p
viral
diagnos
patient
enrol
summar
tabl
influenza
viru
strain
identifi
season
subtyp
patient
identifi
influenza
infect
patient
either
infect
neuraminidas
inhibitor
resist
viru
develop
resist
cours
infect
treatment
adamantan
resist
consid
influenza
isol
collect
studi
resist
least
one
class
antivir
drug
patient
viral
infect
develop
resist
avail
class
antivir
tabl
viru
preval
subtyp
influenza
viru
isol
expect
virus
resist
adamantan
virus
season
isol
identifi
contain
nai
resist
mutat
confer
resist
oseltamivir
possibl
peramivir
mutat
note
time
initi
identif
viru
remain
stabl
consecut
isol
collect
patient
three
immunocompromis
patient
infect
influenza
virus
develop
neuraminidas
inhibitor
resist
treatment
one
patient
infect
develop
novel
delet
mutat
na
gene
case
infect
develop
mutat
case
mutat
aros
treatment
oseltamivir
one
case
peramivir
prolong
clinic
cours
cytokin
respons
acut
infect
measur
serum
nasal
wash
cytokin
measur
gcsf
gmcsf
found
elev
serum
andor
nasal
wash
compar
control
infect
figur
overal
signific
differ
note
respons
immunocompromis
nonimmunocompromis
group
influenza
infect
major
effect
popul
region
world
differ
season
season
emerg
unpredict
pandem
patient
popul
identifi
studi
reflect
popul
washington
dc
metropolitan
region
major
subject
identifi
either
white
black
given
natur
prospect
studi
immunocompromis
patient
possibl
extrem
well
match
compar
group
reason
well
match
tabl
particip
age
mean
age
mean
age
approxim
consist
fact
viru
preval
viru
identifi
studi
much
studi
perform
pandem
postpandem
period
slightli
younger
popul
affect
influenza
typic
influenza
season
number
signific
differ
observ
sever
immunocompromis
nonimmunocompromis
group
immunocompromis
patient
experienc
hospit
longer
length
influenza
viru
shed
sever
diseas
complic
requir
intens
care
mechan
ventil
differ
highlight
patient
import
atrisk
group
enhanc
morbid
mortal
also
consid
group
could
contribut
viral
spread
gener
popul
immunocompromis
patient
studi
shed
viru
mean
approxim
day
like
make
contagi
signific
length
time
mani
patient
asymptomat
signific
portion
time
shed
importantli
number
case
virus
shed
develop
drug
resist
mutat
maintain
transmiss
make
possibl
individu
could
also
sourc
commun
spread
drug
resist
viral
strain
although
mani
immunocompromis
patient
asymptomat
portion
time
infect
exhibit
typic
influenza
symptom
first
day
infect
consist
cytokin
measur
observ
acut
innat
immun
respons
like
princip
respons
mani
acut
symptom
observ
cytokin
measur
nasal
wash
specimen
demonstr
similar
cytokin
respons
immunocompromis
nonimmunocompromis
group
cytokin
elev
consist
report
previous
influenza
infect
serum
similar
elev
note
group
well
although
somewhat
lesser
degre
compar
noninfect
control
despit
similar
acut
innat
respons
group
import
differ
note
overal
symptom
immunocompromis
nonimmunocompromis
group
fewer
overal
symptom
note
immunocompromis
group
influenza
symptom
found
commonli
nonimmunocompromis
group
except
gastrointestin
symptom
like
relat
underli
ill
therapeut
mani
immunocompromis
individu
suffer
gvhd
gut
receiv
toxic
chemotherapeut
agent
overal
trend
inflammatori
system
symptom
occur
often
nonimmunocompromis
group
suggest
although
innat
immun
respons
similar
clinic
manifest
may
possibl
blunt
ill
taken
account
evalu
immunocompromis
patient
influenzalik
ill
significantli
higher
number
radiograph
abnorm
note
immunocompromis
group
point
increas
risk
pulmonari
involv
complic
radiolog
chang
often
absenc
pulmonari
abnorm
physic
exam
preval
nonimmunocompromis
group
import
consid
clinic
presenc
absenc
symptom
sign
may
adequ
indic
diseas
especi
immunocompromis
individu
like
higher
risk
pneumonia
secondari
bacteri
infect
pulmonari
complic
vaccin
remain
cornerston
prevent
influenza
infect
complic
studi
approxim
individu
recruit
vaccin
within
last
year
prior
infect
yet
still
becam
ill
influenza
larger
number
nonimmunocompromis
vaccin
compar
immunocompromis
fact
make
observ
even
concern
signific
number
immunocompet
individu
becam
infect
despit
vaccin
close
match
infect
viru
observ
vaccin
made
studi
somewhat
consist
recent
observ
cdc
recent
year
effect
influenza
vaccin
especi
certain
group
individu
moder
poor
clearli
influenza
vaccin
variabl
efficaci
hard
predict
especi
factor
emerg
virus
special
popul
highlight
work
need
undertaken
find
novel
vaccineprevent
strategi
reduc
diseas
burden
gener
healthi
popul
especi
special
popul
sever
immunocompromis
vaccin
even
hamper
inabl
host
respond
may
requir
reconsid
prevent
diseas
goal
shift
focu
reduc
sever
diseas
complic
prolong
shed
sever
ill
observ
immunocompromis
patient
studi
vaccin
prevent
infect
given
last
step
prevent
morbid
mortal
influenza
therapeut
treatment
antivir
current
gold
standard
preval
antivir
drug
resist
found
studi
warn
ignor
consist
recent
observ
influenza
virus
identifi
studi
resist
least
one
class
antivir
group
patient
virus
resist
major
class
antivir
includ
isol
major
virus
identifi
immunocompromis
patient
receiv
prolong
cours
beyond
day
antivir
therapi
data
conjunct
observ
virus
transmiss
attenu
anim
model
suggest
develop
multidrug
resist
signific
concern
immunocompromis
patient
may
risk
act
host
develop
commun
spread
resist
research
develop
novel
therapi
reevalu
immunocompromis
individu
treat
influenza
undertaken
studi
natur
histori
influenza
extrem
difficult
almost
case
imposs
identifi
exactli
patient
infect
although
rel
small
cohort
observ
studi
one
largest
cohort
sever
immunocompromis
individu
influenza
infect
studi
prospect
date
comparison
individu
nonimmunocompromis
individu
influenza
infect
demonstr
immunocompromis
patient
risk
sever
complic
diseas
may
difficult
prevent
current
vaccin
treat
current
antivir
specif
issu
consid
manag
sever
immunocompromis
host
includ
develop
asymptomat
shed
could
increas
risk
transmiss
develop
multidrug
resist
prolong
antivir
therapi
potenti
high
risk
pulmonari
involv
diseas
lead
secondari
infect
complic
better
understand
basic
human
pathogenesi
influenza
necessari
address
prevent
treat
influenza
individu
way
especi
immunocompromis
clear
current
antivir
adequ
circumst
current
vaccin
strategi
must
improv
care
evalu
individu
case
may
necessari
tailor
treatment
prevent
sever
immunocompromis
individu
like
import
atrisk
popul
